This is Vicore
Our story
Our ambition and strategic priorities
Collaborations and partnerships
Scientific Advisors
Senior Leadership Team
Board of Directors
Science
Scientific rationale
ATRAG MoA in IPF
Intellectual property and orphan drug designation
Publications
Key publications
Posters
Our programs
Pipeline
ASPIRE IPF Ph2b trial
Rare lung diseases
Buloxibutid (C21) – IPF
Future ATRAG indications
Our drug discovery engine
Careers
Our collaborative business model
Open positions
Contact
Media
Press releases (ENG)
Pressmeddelanden (SE)
Image bank
Investors
Investors
Overview
Press releases
Rights Issue, September 2024
The share
Financial reports
Financial calendar
Events & Presentations
Corporate governance
Investor Relations contact
Investerare (SE)
Översikt
Pressmeddelanden
Företrädesemission September 2024
Aktien
Finansiella rapporter
Finansiell kalender
Events & Presentationer
Bolagsstyrning
Bolagsstämma
Investerarkontakt
Patients and caregivers
IPF
Background
Patient stories
Patient advocacy organizations
Transparency
Expanded Access Policy
This is Vicore
Our story
Our ambition and strategic priorities
Collaborations and partnerships
Scientific Advisors
Senior Leadership Team
Board of Directors
Science
Scientific rationale
ATRAG MoA in IPF
Intellectual property and orphan drug designation
Publications
Key publications
Posters
Our programs
Pipeline
ASPIRE IPF Ph2b trial
Rare lung diseases
Buloxibutid (C21) – IPF
Future ATRAG indications
Our drug discovery engine
Careers
Our collaborative business model
Open positions
Contact
Media
Press releases (ENG)
Pressmeddelanden (SE)
Image bank
Investors
Investors
Overview
Press releases
Rights Issue, September 2024
The share
Financial reports
Financial calendar
Events & Presentations
Corporate governance
Investor Relations contact
Investerare (SE)
Översikt
Pressmeddelanden
Företrädesemission September 2024
Aktien
Finansiella rapporter
Finansiell kalender
Events & Presentationer
Bolagsstyrning
Bolagsstämma
Investerarkontakt
Patients and caregivers
IPF
Background
Patient stories
Patient advocacy organizations
Transparency
Expanded Access Policy
Home
/
Investors
/
Corporate governance
/
Code of Conduct and Ethics and Whistleblower Policy
Overview
Press releases
Rights Issue, September 2024
The share
Share monitor
SEC filings
ADR
Shareholders
Ownership board and management
Share issues
Share capital development
Analyst coverage
Listing prospectus
Financial reports
Financial calendar
Events & Presentations
Corporate governance
General meeting
Corporate governance reports
Nomination Committee
Board of Directors
Board Committees
Management
Remuneration and incentives
Auditors
Articles of association
Code of Conduct
Subscribe to press releases
Investor Relations contact
Code of Conduct and Ethics and Whistleblower Policy
Code of Conduct and Ethics and Whistleblower Policy